Day: May 12, 2022

Generated $12.3 million of revenue and other operating income in the first half of fiscal year 2022 LONDON, May 12, 2022 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (“Arqit”), a global leader in quantum encryption technology, today announced its operational and financial results for the first half of its fiscal year ending (“FYE”) 30 September 2022. Recent Operational HighlightsSigned an enterprise licence with Virgin Orbit for QuantumCloud™ to protect its launch and space solutions businesses, which we delivered on and recognised revenue in the first half of FYE 2022. Signed an enterprise licence with AUCloud, Australia’s sovereign cloud infrastructure-as-a-service provider, for QuantumCloud™ to provide quantum encryption services, which we delivered on and recognised revenue in the first half of FYE 2022. Delivered...

MALVERN, Pa., May 12, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2022. First Quarter 2022 HighlightsExceeded guidance – First quarter 2022 revenue of $14.2 million, exceeded previously issued guidance of $13.0 million to $14.0 million Increased NeuroStar System revenue 108% over the first quarter of 2021. First quarter 2022 system revenue increased 29% sequentially as compared to fourth quarter 2021Recent Operational HighlightsReceived FDA 510(k) clearance for Obsessive-Compulsive Disorder for the treatment of adult patientsEntered into long-term...

Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plans to submit IND for XTX301, a tumor-selective IL-12, in second half of 2022 Strong financial position with $177 million in cash and cash equivalents as of March 31, 2022, with cash runway anticipated into first half of 2024 WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business highlights and reported financial results for the first quarter ended March 31, 2022. “Leveraging our geographically precise solutions (GPS) platform, we are developing a pipeline of tumor-selective immunotherapies...

– Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program – – New preclinical data presented at the 45th Annual Association for Research in Otolaryngology Conference (ARO) supporting DB-OTO and emphasizing platform focus on cell-selective transgene expression – – Preclinical data to be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting DB-OTO, AAV.103 and AAV.104 – BOSTON, May 12, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and...

Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and frequency, with additional single and multidose data expected throughout 2022 Clinical data also expected in 2022 from Huntington’s disease (WVE-003) and Duchenne muscular dystrophy (WVE-N531) trials Robust preclinical datasets for first-in-class AATD program demonstrate restoration of levels of AAT relevant for potential lung protection and reduction of liver-damaging aggregates with GalNAc AIMers; IND enabling toxicology studies for lead AATD candidate on-track to initiate in 3Q 2022 Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq:...

Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 million MISSISSAUGA, Ontario, May 12, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2022 ended March 31, 2022 (“Q2” and “H2”), with record sales and strong earnings, plus ongoing progress upon its strategic goal of increasing the proportion of revenues derived from medical devices to thereby continue growing sales, margins, and earnings. Management Discussion Q2 revenues achieved a record level of $4.9 million, up 12% from Q2 2021, as Microbix continues to emphasize operational excellence and the sale of innovative, proprietary, and branded medical devices. Microbix’s viral transport medium (branded “DxTM™”) contributed...

Higher Commodity Prices, Cost Discipline Drive a 127% Increase in Net Operating IncomeGrowing Interest in Proposed LNG Project NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES HighlightsDuring Q1 2022:Generated Net Operating Income1 (“NOI”) of $47.3 million ($0.30 per basic and fully diluted share), up 127% from the comparable period in 2021; Generated Adjusted Funds Flow from Operations1 (“AFFO”) of $45.1 million ($0.29 per basic and fully diluted share), up 203%; generated net income of $10.5 million ($0.07 per basic and fully diluted share), up 154% from the comparable period in 2021; Generated petroleum and natural gas revenue of $129.8 million, up 48% from the comparable period in 2021; Netback per boe increased 146% to $12.98/boe from $5.27/boe in the comparable period in 2021; Total...